Bertil Olofsson
About
Bertil Olofsson is a scholar working on Cardiology and Cardiovascular Medicine, Analytical Chemistry and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Bertil Olofsson has authored 57 papers receiving a total of 11.7k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Cardiology and Cardiovascular Medicine, 8 papers in Analytical Chemistry and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Bertil Olofsson's work include Heart Failure Treatment and Management (21 papers), Blood Pressure and Hypertension Studies (16 papers) and Cardiac pacing and defibrillation studies (11 papers). Bertil Olofsson is often cited by papers focused on Heart Failure Treatment and Management (21 papers), Blood Pressure and Hypertension Studies (16 papers) and Cardiac pacing and defibrillation studies (11 papers). Bertil Olofsson collaborates with scholars based in Sweden, United States and United Kingdom. Bertil Olofsson's co-authors include Salim Yusuf, John J.V. McMurray, Karl Swedberg, Eric L. Michelson, Jan Östergren, Marc A. Pfeffer, Christopher B. Granger, Peter Held, Dag Elmfeldt and Alberto Zanchetti and has published in prestigious journals such as The Lancet, Circulation and Journal of the American College of Cardiology.
In The Last Decade
Bertil Olofsson
57 papers receiving 11.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Bertil Olofsson Sweden | 31 | 10.1k | 2.9k | 1.5k | 845 | 521 | 57 | 11.7k | ||
| Victor Shi United States | 48 | 11.8k 1.2× | 3.0k 1.1× | 2.3k 1.6× | 1.4k 1.6× | 788 1.5× | 120 | 13.4k | ||
| Sandra J. Taler United States | 41 | 5.8k 0.6× | 1.9k 0.7× | 1.7k 1.2× | 2.1k 2.5× | 572 1.1× | 100 | 11.5k | ||
| Martin Lefkowitz United States | 55 | 10.0k 1.0× | 2.6k 0.9× | 2.4k 1.6× | 1.6k 1.9× | 841 1.6× | 172 | 12.7k | ||
| Vasilios Papademetriou United States | 54 | 7.2k 0.7× | 2.5k 0.9× | 758 0.5× | 1.8k 2.2× | 568 1.1× | 300 | 10.4k | ||
| Renata Cífková Czechia | 37 | 7.9k 0.8× | 2.5k 0.9× | 1.1k 0.7× | 1.8k 2.1× | 826 1.6× | 217 | 12.3k | ||
| Peter Held Sweden | 23 | 8.4k 0.8× | 2.1k 0.7× | 1.3k 0.9× | 1.4k 1.7× | 407 0.8× | 37 | 9.5k | ||
| Björn Dahlöf Sweden | 41 | 8.6k 0.9× | 3.0k 1.1× | 628 0.4× | 1.5k 1.7× | 610 1.2× | 94 | 10.7k | ||
| Eric L. Michelson United States | 58 | 17.7k 1.7× | 3.2k 1.1× | 2.3k 1.5× | 2.0k 2.4× | 1.2k 2.3× | 192 | 20.9k | ||
| Gastone Leonetti Italy | 39 | 5.5k 0.5× | 1.8k 0.6× | 497 0.3× | 935 1.1× | 367 0.7× | 197 | 7.0k | ||
| Stephen J. Greene United States | 53 | 8.2k 0.8× | 2.1k 0.7× | 1.7k 1.2× | 1.3k 1.5× | 1.5k 2.8× | 305 | 11.8k |
Countries citing papers authored by Bertil Olofsson
Since
Specialization
Citations
This map shows the geographic impact of Bertil Olofsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bertil Olofsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bertil Olofsson more than expected).
Fields of papers citing papers by Bertil Olofsson
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Bertil Olofsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bertil Olofsson. The network helps show where Bertil Olofsson may publish in the future.
Co-authorship network of co-authors of Bertil Olofsson
This figure shows the co-authorship network connecting the top 25 collaborators of Bertil Olofsson. A scholar is included among the top collaborators of Bertil Olofsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bertil Olofsson. Bertil Olofsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chang, Su Min, Christopher B. Granger, Peter A. Johansson, et al.. (2010). Efficacy and Safety of Angiotensin Receptor Blockade are Not Modified by Aspirin in Patients with Chronic Heart Failure: A Cohort Study from the Candesartan in Heart failure – Assessment of Reduction in Mortality and morbidity (CHARM) Programme. European Journal of Heart Failure. 12(7). 738–745.
2.
Granger, Bradi B., Inger Ekman, Christopher B. Granger, et al.. (2009). Adherence to Medication According to Sex and Age in the CHARM Programme. European Journal of Heart Failure. 11(11). 1092–1098.
3.
Meredith, Peter, Jan Östergren, Inder S. Anand, et al.. (2008). Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program. Journal of the American College of Cardiology. 52(24). 2000–2007.
4.
Weir, Robin A.P., John J.V. McMurray, Margareta Puu, et al.. (2008). Efficacy and Tolerability of Adding an Angiotensin Receptor Blocker in Patients with Heart Failure Already Receiving an Angiotensin-Converting Inhibitor Plus Aldosterone Antagonist, With or Without a Beta Blocker. Findings from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM)-Added Trial. European Journal of Heart Failure. 10(2). 157–163.
5.
Lewis, Eldrin F., Gervasio A. Lamas, Eileen O’Meara, et al.. (2006). Characterization of Health-Related Quality of Life in Heart Failure Patients with Preserved Versus Low Ejection Fraction in CHARM. European Journal of Heart Failure. 9(1). 83–91.
6.
McMurray, John J.V., James B. Young, Mark E. Dunlap, et al.. (2006). Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial. American Heart Journal. 151(5). 985–991.
7.
O’Meara, Eileen, Eldrin F. Lewis, C. B. Granger, et al.. (2005). Patient Perception of the Effect of Treatment with Candesartan in Heart Failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure. 7(4). 650–656.
8.
Solomon, Scott D., Bertil Olofsson, Peter Finn, et al.. (2004). 1069-113 Cause of death across full spectrum of ventricular function in patients with heart failure: The CHARM study. Journal of the American College of Cardiology. 43(5). A180–A180.
9.
Papademetriou, Vasilios, Csaba Farsang, Dag Elmfeldt, et al.. (2004). Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension. Journal of the American College of Cardiology. 44(6). 1175–1180.
10.
McMurray, John J.V., Chim C. Lang, Karl Swedberg, et al.. (2004). 1108-109 Low hemoglobin is an independent predictor of adverse fatal and nonfatal outcomes in both reduced and preserved systolic function chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity program (CHARM). Journal of the American College of Cardiology. 43(5). A197–A197.
11.
McMurray, John J.V., Jan Östergren, Michael Pfeffer, et al.. (2003). Clinical Features and Contemporary Management of Patients with Low and Preserved Ejection Fraction Heart Failure: Baseline Characteristics of Patients in the Candesartan in Heart failure—Assessment of Reduction in Mortality and Morbidity (CHARM) Programme. European Journal of Heart Failure. 5(3). 261–270.
12.
McMurray, John J.V., Jan Östergren, Karl Swedberg, et al.. (2003). CHARM IN-VESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED LEFT-VENTRICULAR SYSTOLIC FUNCTION TAKING ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS: THE CHARM-ADDED TRIAL. The Lancet. 362. 767–771.
13.
Yusuf, Salim, Marc A. Pfeffer, Karl Swedberg, et al.. (2003). Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. The Lancet. 362(9386). 777–781.
14.
Swedberg, Karl, Marc A. Pfeffer, C. B. Granger, et al.. (1999). Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design. Journal of Cardiac Failure. 5(3). 276–282.
15.
Aberg, Judith A., Bertil Abrahamsson, Margaretha Grind, G. Nyberg, & Bertil Olofsson. (1997). Bioequivalence, pharmacokinetic and pharmacodynamic response to combined extended release formulations of felodipine and metoprolol in healthy volunteers. European Journal of Clinical Pharmacology. 52(6). 471–477.
16.
Sandberg, Anders, et al.. (1993). Steady-State Bioavailability and Day-to-Day Variability of a Multiple-Unit (CR/ZOK) and a Single-Unit (OROS) Delivery System of Metoprolol After Once-Daily Dosing. Pharmaceutical Research. 10(1). 28–34.
17.
Lundborg, Per, et al.. (1990). Pharmacokinetic and Pharmacodynamic Evaluation of Metoprolol Controlled Release (CR/ZOK) 50 mg in Young Subjects. The Journal of Clinical Pharmacology. 30(S2). S28–32.
18.
Dahl�f, C., et al.. (1990). Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects ? a comparison with atenolol. European Journal of Clinical Pharmacology. 38(6). 571–578.
19.
Lücker, P W, et al.. (1990). Pharmacokinetic and Pharmacodynamic Comparison of Metoprolol CR/ZOK Once Daily with Conventional Tablets Once Daily and in Divided Doses. The Journal of Clinical Pharmacology. 30(S2). S17–27.
20.
Dimenäs, E., C Dahlöf, Bertil Olofsson, & Ingela Wiklund. (1989). CNS‐related subjective symptoms during treatment with beta 1‐ adrenoceptor antagonists (atenolol, metoprolol): two double‐blind placebo controlled studies.. British Journal of Clinical Pharmacology. 28(5). 527–534.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Victor Shi Breakdown of academic impact, for papers by Sandra J. Taler Breakdown of academic impact, for papers by Martin Lefkowitz Breakdown of academic impact, for papers by Vasilios Papademetriou Breakdown of academic impact, for papers by Renata Cífková Breakdown of academic impact, for papers by Peter Held Breakdown of academic impact, for papers by Björn Dahlöf Breakdown of academic impact, for papers by Eric L. Michelson Breakdown of academic impact, for papers by Gastone Leonetti Breakdown of academic impact, for papers by Stephen J. Greene